Back to top

Guardant Health Falls as Recent Rally Appears to Cool

Guardant Health (GH) is down 4.9% today. Here is some analysis on what might have caused this price movement.

Analysis: The pullback appears more consistent with profit-taking than with any fresh negative company-specific announcement. Guardant had rallied on major positive reimbursement and guideline catalysts earlier this month, and several firms also lifted price targets ahead of the company’s July 30, 2026 second-quarter report, so today’s decline could be investors locking in gains after that run. ([investors.guardanthealth.com](https://investors.guardanthealth.com/press-releases/press-releases/2026/UnitedHealth-Group-Now-Covers-Guardant-Healths-Shield-Blood-Test-for-Colorectal-Cancer-Screening/default.aspx?utm_source=openai))

Details:

  • GH finished at $148.51, down about 4.7% from the prior close, after opening at $155.84 and trading as low as $147.895 during the session.
  • On July 1, Guardant said UnitedHealth coverage for the Shield colorectal cancer blood test expanded access to roughly 100 million covered lives, adding to an already strong run in the shares earlier this month. ([investors.guardanthealth.com](https://investors.guardanthealth.com/press-releases/press-releases/2026/UnitedHealth-Group-Now-Covers-Guardant-Healths-Shield-Blood-Test-for-Colorectal-Cancer-Screening/default.aspx?utm_source=openai))
  • Guardant’s first-quarter 2026 revenue rose 48% to $301.7 million, and the company raised full-year 2026 revenue guidance to $1.30 billion to $1.32 billion. ([investors.guardanthealth.com](https://investors.guardanthealth.com/press-releases/press-releases/2026/Guardant-Health-Reports-First-Quarter-2026-Financial-Results-and-Increases-2026-Revenue-Guidance/default.aspx))
  • Recent market coverage shows multiple analyst price-target increases in July and notes that Guardant is scheduled to report second-quarter results on July 30, which can also increase short-term volatility. ([stockanalysis.com](https://stockanalysis.com/stocks/gh/))

    • Sources:

    Guardant Health, SEC, Stock Analysis

    Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

    $GH Insider Trading Activity

    GH Insider Trades

    $GH insiders have traded $GH stock on the open market 63 times in the past 6 months. Of those trades, 1 have been purchases and 62 have been sales.

    Here’s a breakdown of recent trading of $GH stock by insiders over the last 6 months:

    • AMIRALI TALASAZ (Co-Chief Executive Officer) has made 0 purchases and 19 sales selling 520,000 shares for an estimated $67,405,344.
    • HELMY ELTOUKHY (Co-Chief Executive Officer) has made 0 purchases and 7 sales selling 100,000 shares for an estimated $12,629,968.
    • KUMUD KALIA (Chief Information Officer) has made 1 purchase buying 600 shares for an estimated $78,456 and 6 sales selling 49,618 shares for an estimated $5,067,010.
    • JOHN G. SAIA (Chief Legal Officer) has made 0 purchases and 5 sales selling 30,000 shares for an estimated $3,381,064.
    • CHRIS FREEMAN (Chief Commercial Officer) sold 24,406 shares for an estimated $2,896,360
    • TERILYN J. MONROE (Chief People Officer) has made 0 purchases and 4 sales selling 12,403 shares for an estimated $1,333,051.
    • MEGHAN V. JOYCE has made 0 purchases and 4 sales selling 10,000 shares for an estimated $1,269,808.
    • STEVE E. KROGNES sold 9,294 shares for an estimated $1,231,521
    • IAN T CLARK sold 6,876 shares for an estimated $735,048
    • MICHAEL BRIAN BELL (Chief Financial Officer) has made 0 purchases and 2 sales selling 5,000 shares for an estimated $518,351.
    • MEDINA MANUEL HIDALGO has made 0 purchases and 5 sales selling 3,550 shares for an estimated $382,920.
    • MUSA TARIQ has made 0 purchases and 6 sales selling 2,763 shares for an estimated $341,563.
    • MYRTLE S POTTER sold 1,556 shares for an estimated $204,084

    To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

    EARLY ACCESS
    Receive GH Data Alerts
    Real-time alerts on filings, insider trades, and market signals — before everyone else.
    Get Alerts →

    $GH Hedge Fund Activity

    We have seen 235 institutional investors add shares of $GH stock to their portfolio, and 207 decrease their positions in their most recent quarter.

    Here are some of the largest recent moves:

    To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

    $GH Analyst Ratings

    Wall Street analysts have issued reports on $GH in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

    Here are some recent analyst ratings:

    • BTIG issued a "Buy" rating on 02/20/2026

    To track analyst ratings and price targets for $GH, check out Quiver Quantitative's $GH forecast page.

    $GH Price Targets

    Multiple analysts have issued price targets for $GH recently. We have seen 21 analysts offer price targets for $GH in the last 6 months, with a median target of $160.0.

    Here are some recent targets:

    • Shannon O'Callaghan from Morgan Stanley set a target price of $175.0 on 07/09/2026
    • Patrick Donnelly from Citigroup set a target price of $215.0 on 07/08/2026
    • Michael Ryskin from B of A Securities set a target price of $190.0 on 07/06/2026
    • Vijay Kumar from Evercore ISI Group set a target price of $200.0 on 07/06/2026
    • Eve Burstein from Bernstein set a target price of $200.0 on 07/02/2026
    • Mark Massaro from BTIG set a target price of $190.0 on 07/01/2026
    • Subbu Nambi from Guggenheim set a target price of $160.0 on 06/29/2026

    This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.

    Read full article here »

    In-Depth Zacks Research for the Tickers Above

    Normally $25 each - click below to receive one report FREE:

    Guardant Health, Inc. (GH)